06:17 AM EDT, 03/23/2026 (MT Newswires) -- GSK (GSK) said Monday that Japan's Ministry of Health, Labor and Welfare has granted orphan drug designation to risvutatug rezetecan to treat small-cell lung cancer.
The designation was supported by preliminary clinical data showing "durable" responses in patients with extensive-stage small-cell lung cancer in a trial, the company said.
GSK shares were down 2.3% in premarket activity.